Business Wire

AZ-EDGIO

7.2.2024 12:01:32 CET | Business Wire | Press release

Share
Edgio Partners with KPS to Support Online Retailers with Their Transition to Composable Web Architecture

Edgio, the platform of choice for speed, security, and simplicity at the edge, today announced a partnership with KPS, the leading partner for customer-centric business transformation. KPS is known for implementing best-of-breed, agile technology that increases website conversion, customer loyalty, and revenue per client.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207602775/en/

To meet increasingly demanding consumer expectations, KPS’s enterprise retail clients require the flexibility, scalability, agility, speed-to-market and cost efficiency that a composable web architecture provides. With a modular approach at its core, composable commerce enables brands to select best-of-breed solutions and customize a tech stack that more closely reflects their unique business requirements.

After reviewing the market for a technology partner to support them, KPS chose Edgio to help accelerate that composability evolution for their clients. Edgio’s Sites solution enables companies to develop front-end applications at the edge with ease, using 40+ frameworks with automated deployment.

Edgio’s patented iterative migration approach will now allow KPS to evolve their clients’ applications to become headless and more composable over time, rather than through costly one-off implementations, proving value and return at every stage.

Alongside headless capabilities, all the features of the Edgio Applications platform – dynamic caching, real-time customer experience monitoring, predictive prefetching, and best-of-breed security solutions, are easily accessible via fixed-price bundles that can be purchased at an entry level that makes sense to each individual client. This is a game changer for KPS as it means they can offer clients a competitive pricing model that scales with their business growth.

“It's an exciting relationship for KPS, building on our principles of quality, security, and performance that allow us to provide more composable and future-proofed solutions. It provides our clients access to best-of-breed security and online experience capabilities,” said Tim Hillman, CTO (UK) at KPS. "We are delighted to collaborate with Edgio, a team of highly skilled and experienced security and application experts. Their unwavering commitment to KPS and our clients is evident in their exceptional dedication and support. We look forward to strengthening our trusted partnership and we eagerly anticipate the innovative solutions Edgio will bring to our clients in the future.”

“With over two decades of experience creating unique digital solutions and exceptional customer experience, KPS is known for helping companies implement best-of-breed technology,” said Emma Whitmore, Group Vice President, EMEA at Edgio. "We are thrilled to be partnering with KPS to deploy high-performing, brand-building experiences that delight their customers. Aligning our security and performance technology with their industry know-how and passion for successful transformations, will mean their retail clients can innovate and adapt quickly to changing business needs.”

About Edgio

Edgio (NASDAQ: EGIO) helps companies deliver online experiences and content faster, safer, and with more control. Its developer-friendly, globally scaled edge network, combined with fully integrated application and media solutions, provides a single platform for the delivery of high-performing, secure web properties and streaming content. Through this fully integrated platform and end-to-end edge services, companies can deliver content quicker and more securely, thus boosting overall revenue and business value. To learn more, visit edg.io and follow us on Twitter, LinkedIn, and Facebook.

About KPS

KPS specialises in composable commerce across the entire customer journey, from app, loyalty and data insights to marketplaces, multichannel retailing and digital growth. Working with leading consumer and business-to-business brands as a trusted partner, KPS creates enduring value by understanding customers, their needs and behaviour, to deliver truly engaging experiences in a rapidly changing environment.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207602775/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release

Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release

Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye